Published 4 issues per year
ISSN Print: 0893-9675
ISSN Online: 2162-6448
Indexed in
Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity
ABSTRACT
The FLT3-ligand is a molecule implicated in hematopoiesis. The aim of the present study was to detect any possible connections between serum levels of FLT3-L and multiple myeloma (MM) proliferation markers, such as serum levels of interleukin-6 (IL-6), B-cell activating factor (BAFF), beta-2 microglobulin (B2M), CRP and LDH, as well the percentage of bone marrow infiltration and the plasma cells' proliferation marker Ki-67 PI. We measured the above parameters in 58 patients with active MM. All circulating markers were significantly higher in MM patients compared to controls (p < 0.001 for all cases), and all values were increasing in parallel with disease stage (p < 0.001 for all cases). Positive correlations between FLT3-L were noted with serum levels of BAFF (p < 0.003), IL-6 (p < 0.002), CRP (p < 0.0001), LDH (p < 0.001), and BM Ki-67 PI (p = 0.012), whereas only trends of correlation were noted with the B2M value and the percentage of infiltration. It seems that the increased serum levels of circulating FLT3-L, in parallel with MM activity, reflect their increased presence in the bone marrow microenvironment, probably as an effect of increased angiogenesis and myelosuppression. Consequently, they are potential markers of disease activity.
-
Kazi Julhash U., Rönnstrand Lars, FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications, Physiological Reviews, 99, 3, 2019. Crossref
-
Steiner Normann, Jöhrer Karin, Plewan Selina, Brunner-Véber Andrea, Göbel Georg, Nachbaur David, Wolf Dominik, Gunsilius Eberhard, Untergasser Gerold, The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis, Cancers, 12, 9, 2020. Crossref
-
Sun Ming, Liu Xuefeng, Zhao Wenyan, Zhang Bin, Deng Peng, Circ_0058063 contributes to cisplatin-resistance of bladder cancer cells by upregulating B2M through acting as RNA sponges for miR-335-5p, BMC Cancer, 22, 1, 2022. Crossref